Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.
Pediatr Blood Cancer
; 62(1): 5-11, 2015 Jan.
Article
in En
| MEDLINE
| ID: mdl-25175627
Neuroblastoma is unique amongst common pediatric cancers for its expression of the norepinephrine transporter (NET), enabling tumor-selective imaging and therapy with radioactive analogues of norepinephrine. The majority of neuroblastoma tumors are avid for (123)I-metaiodobenzaguanidine (mIBG) on imaging, yet the therapeutic response to (131) I-mIBG is only 30% in clinical trials, and off-target effects cause short- and long-term morbidity. We review the contemporary understanding of the tumor-selective uptake, retention, and efflux of meta-iodobenzylguanidine (mIBG) and strategies currently in development for improving its efficacy. Combination treatment strategies aimed at enhancing NET are likely necessary to reach the full potential of (131)I-mIBG therapy.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Radiopharmaceuticals
/
3-Iodobenzylguanidine
/
Norepinephrine Plasma Membrane Transport Proteins
/
Iodine Radioisotopes
/
Neuroblastoma
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Pediatr Blood Cancer
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Year:
2015
Document type:
Article
Country of publication:
United States